Ligand Pharmaceuticals LGND Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $124.45M+3,187% | -$4.03M-108% | $52.15M+256% | -$33.36M-153% | ||
| $33.78M-4.2% | $35.24M-3.5% | $36.52M-29.1% | $51.53M+0.9% | ||
| $46.85M+14.0% | $41.09M+59.6% | $25.74M-57.3% | $60.29M+55.4% | ||
| $49.36M-49.1% | $97.05M+95.4% | $49.66M-64.0% | $137.85M+74.9% | ||
| $452K-75.2% | $1.82M-48.3% | $3.52M-80.4% | $17.92M+105% | ||
| -$377.32M-163% | -$143.66M-1,130% | -$11.68M-107% | $170.91M— | ||
| $428.22M+341% | $97.14M— | —— | -$275.99M-94.5% | ||
| $102.62M+108% | $49.35M— | —— | $25.48M+185% | ||
| $48.91M-48.6% | $95.23M+105% | $46.34M-61.4% | $119.93M+71.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ligand Pharmaceuticals's cash flow data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.